Frank Rizzo, CEO of XenaCare, said: “As one of the largest food retailers in the United States, Winn-Dixie provides Cobroxin with significant retail coverage throughout the Southeastern United States. We are excited to be working closely with Winn-Dixie to continue to build consumer awareness about our Cobroxin branded pain relievers.”
XenaCare claimed that the Cobroxin is the first OTC pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Many other Stage 2 drugs require prescriptions, including Tylenol 3, Percocet, and Vicodin.
Cobroxin is currently available as an oral spray for treating migraine headaches, neck aches, shoulder pain, cramps, lower back pain and neuralgia and is also available as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
XenaCare was granted a license by Nutra Pharma, the biotechnology company that developed and currently manufactures Cobroxin, to market and distribute Cobroxin within the US.